Author

Z. Alali

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

O. Reizes· 3 shared E. Esakov· 2 shared J. Lathia· 2 shared L. Trestan· 2 shared M. P. Horowitz· 2 shared A. Hajjar· 1 shared A. S. Joehlin-Price· 1 shared C. Braley· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

O. Reizes

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A Novel Non-Invasive Epithelial Ovarian Cancer Mouse Model Of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Z. Alali, M. P. Horowitz, D. Chau, L. Trestan, J. Hao, P. Qi, E. Esakov, R. L. DeBernardo, J. S. Yu, O. Reizes

This paper introduces a novel non-invasive mouse model of HIPEC to study its efficacy in epithelial ovarian cancer.

bioRxiv · May 16, 2021 · PreprintCancer Biology

Single-Cell Analysis of Hyperthermic Intraperitoneal Chemotherapy Treated Tumors Reveals Distinct Cellular and Molecular Responses

M. P. Horowitz, Z. Alali, T. Alban, C. Hong, E. Esakov, T. H. Hwang, J. Lathia, C. M. Michener, R. DeBernardo, O. Reizes

This study uses single-cell RNA-seq to analyze tumor responses to HIPEC in ovarian cancer patients, identifying distinct cellular and molecular changes.

bioRxiv · Oct 5, 2020 · PreprintCancer Biology

Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy

L. Chambers, E. L. Esakov, C. Braley, L. Trestan, Z. Alali, D. Bayik, J. Lathia, N. Sangwan, P. Bazeley, A. S. Joehlin-Price, M. Dwidar, A. Hajjar, P. P. Ahern, J. Claesen, P. Rose, , O. Reizes

This study shows that antibiotic treatment disrupts the gut microbiome, leading to increased resistance to cisplatin in ovarian cancer models.

bioRxiv · Jun 16, 2020 · PreprintCancer Biology